Artelo Biosciences Q2 FY26 net loss narrows 24.65% to USD 2.43 million - ARTL News | RalliesArtelo Biosciences Q2 FY26 net loss narrows 24.65% to USD 2.43 million
A
ARTL• Q2 FY26 financial results
- Artelo Biosciences posted a net loss of USD 2.43 million, narrowing from USD 3.22 million a year earlier.
- Operating loss narrowed to USD 2.51 million as operating expenses fell to USD 2.51 million from USD 3.15 million.
- Research and development expense dropped to USD 876,000 from USD 1.87 million, mainly on lower CAReS trial spending.
- General and administrative costs rose to USD 1.63 million from USD 1.28 million.
- Cash, cash equivalents and investments totaled USD 4.2 million at June 30, 2026; the company entered a USD 6.53 million at-the-market program.
•
